Medullary thyroid cancer

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
3 Unique sponsors
3 Unique IMPs
4 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Kinase inhibitor 2 substances
Unknown / small molecule 1 substance
Phase I/II: 2 Phase IV: 1 Phase I (First in Human): 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase I/II

2 trials
  • Ellipses Pharma Limited Commercial
    EP0031
    2022-501636-42-00 5 countries 2023 n=127 Orphan
    Recruiting
  • Loxo Oncology Inc. Commercial
    SELPERCATINIB
    2023-507703-63-00 5 countries 2020 n=25
    Ended

Phase IV

1 trial
  • Exelixis Inc. Commercial
    CABOZANTINIB
    2024-516480-90-00 4 countries 2015 n=10 Orphan
    Ended

Phase I (First in Human)

1 trial
  • Loxo Oncology Inc. Commercial
    IMP not specified
    2023-507702-13-00 5 countries 2017 n=128
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Loxo Oncology Inc. Commercial 2 Phase I (First in Human), Phase I/II 0
Exelixis Inc. Commercial 1 Phase IV 0
Ellipses Pharma Limited Commercial 1 Phase I/II 1
New trials by year
2020
1
2023
1
← All indication landscapes